AI identifies suitable herbal synergies, delivery systems, and target resonance bands: Greenspace Herbs Founder

Ayurveda has been used for thousands of years, but that history does not easily fit into Western regulatory frameworks, says Shafiulla Hirehal Nuruddin, Founder and MD, Greenspace Herbs

We are seeing a global shift toward Quantum Ayurveda. How is AI and Quantum Physics helping improve the way we test and verify botanical ingredients in the global nutraceutical industry?

AI allows us to understand the interactions of hundreds of compounds in herbs, which is beyond traditional testing. Quantum physics takes it one step further. It examines subatomic energy signatures, and “bio-vibrational” states that extend beyond basic chemistry.

AI then uses the data to predict bioavailability and molecular synergy, effectively creating a “digital twin” of the herb to ensure consistent potency. It is a tech way to support the holistic principles of Quantum Ayurveda with measurable, scientific standards.

As the industry moves beyond simple chemical extraction, what role will “Energized” active ingredients (such as EASI™ technology) play in the next generation of high-potency supplements?

I think the notion of ‘energized ingredients’ is interesting – basically, that the active components are more bioavailable and work faster in the body. The concept of “energized” ingredients is interesting, basically ensuring that the active compounds are more bioavailable and act more quickly in the body. EASI™ “energized” ingredients use quantum chemistry to optimize the molecular behavior to ensure maximum cellular uptake.

This tech allows for greater potency at much lower doses. It is a move away from basic chemical extraction to AI-enabled, bio-enhanced delivery systems. It basically connects the ancient principles with modern precision for more “intelligent” nutraceuticals.

Given the expansion into foreign markets, what are the primary challenges in aligning traditional Ayurvedic formulations with the stringent clinical and pharmaceutical standards of Western regulatory bodies?

This is the most difficult part, probably. Western regulators, like the FDA and EFSA, demand robust clinical data – randomized placebo controlled trials with distinct endpoints. Ayurveda has been used for thousands of years, but that history does not easily fit into Western regulatory frameworks.

The challenge is to not only show it works, but to speak the language regulators understand. We also have different standards between countries, so it is hard to grow globally. The good news is that more regulators are beginning to engage with traditional medicine.

As demand for rare botanicals surges, how can the industry balance the need for high-yield, high-tech molecular extraction with the ethical and environmental necessity of sustainable herb sourcing?

This is important to me. We are at a crossroads; demand for rare botanicals is increasing. High-tech extraction can actually help; you need less plant material to get the same benefit, which reduces pressure on wild populations. But technology alone won’t do it. We need farmers. Rare herbs are becoming rarer and we need cultivation programs.

What we need is traceability so that consumers know where their ingredients come from. The last thing the industry needs is to innovate while we are burning through the resources we are relying on. There are some companies doing exceptional work here, but the industry as a whole needs to put sustainability before speed to market.

What market trends will matter most for herbal ingredient companies over the next 2–3 years, especially around evidence standards, product differentiation, and global growth in preventive wellness?

Consumers are smarter. They have read the labels and have taken the supplements, they are more skeptical of big promises. Transparency is the trend — third party testing, clear sourcing information, and actual clinical data. You can’t get away with unique buzzwords anymore, proof is what counts. Preventive wellness is certainly on the rise, particularly around stress, sleep and metabolic health, but consumers want supplements that deliver, not just supplements that look good on a bottle.

Which forces are most likely to shape demand for plant-based wellness products in the coming years: personalization, clean-label positioning, or clinical credibility?

If I had to rank them, clinical credibility wins out. Personalization is exciting and will continue to grow but it is only useful if the product underneath is evidence-backed. Clean-label positioning speaks to people who care about what they put into their body and that is important. But ultimately, if a supplement doesn’t work, neither personalization nor a clean label will bring customers back. The brands that survive the next decade will be the brands that invest money in real research.”

What were the main challenges in bringing your latest launch to market, particularly around validation, compliance, and differentiating the product in a crowded wellness space?

It is more difficult to launch anything new in wellness today than it was five years ago. Validation takes time; you can’t rush clinical studies or proper quality testing. If you are selling in different countries with different rules, compliance is a maze. And the differentiation is too much competition.

Everyone has a story, everyone has their USP. The challenge is to make sure your story has something to say. And those who embrace this grind, and work honestly, are the successful brands.

How is the use of artificial intelligence to map molecular synergies between different herbs changing the way we approach the formulation of preventive healthcare products?

AI identifies suitable herbal synergies, delivery systems, and target resonance bands for specific results (metabolic/neurovascular). This knowledge guides formulation prior to pilot batches and prevents blind assembling of ingredients without knowledge of interaction.

Looking toward 2030, what role do you expect “Metastable” energy forms and molecular resonance to play in the development of next-generation supplements for chronic lifestyle diseases?

Metastable energy forms of high-energy molecular states will dramatically accelerate absorption and cell repair by 2030. The supplements will be able to “tune” into the vibrational frequencies of target organs through molecular resonance, ensuring pinpoint accuracy for chronic disease.

This leads to ‘intelligent signaling’ in the industry where micro-doses avoid metabolic resistance to reboot cellular health. At the end of the day, activated release wearable will turn supplements from passive pills to active biological instructions in real time.